<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">tumors</journal-id><journal-title-group><journal-title xml:lang="ru">Malignant tumours</journal-title><trans-title-group xml:lang="en"><trans-title>Malignant tumours</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2224-5057</issn><issn pub-type="epub">2587-6813</issn><publisher><publisher-name>Rosoncoweb</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18027/2224-5057-2019-10-3s1-15-20</article-id><article-id custom-type="elpub" pub-id-type="custom">tumors-726</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group></article-categories><title-group><article-title>Диагностика и лечение распространённых форм рака яичников III–IV стадии</article-title><trans-title-group xml:lang="en"><trans-title>Диагностика и лечение распространённых форм рака яичников III–IV стадии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саевец</surname><given-names>В. В.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Челябинск</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Важенин</surname><given-names>А. В.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Челябинск</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ульрих</surname><given-names>Е. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мухин</surname><given-names>А. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Челябинск</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Таратонов</surname><given-names>А. В.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Челябинск</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шмидт</surname><given-names>А. В.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Челябинск</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ГБУЗ ЧОКЦОиЯМ; ФГБОУ ВО ЮУГМУ Минздрава России</institution><country>Russian Federation</country></aff><aff xml:lang="ru" id="aff-2"><institution>ФГБОУ ВО «СЗГМУ им. И. И. Мечникова»;  ФГБУ «НМИЦ онкологии им. Н. Н. Петрова» МЗ РФ; НИЛ ФГБУ «НМИЦ им. В. А, Алмазова»</institution><country>Russian Federation</country></aff><aff xml:lang="ru" id="aff-3"><institution>ГБУЗ ЧОКЦОиЯМ</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>02</day><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>3s1</issue><fpage>15</fpage><lpage>20</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Саевец В.В., Важенин А.В., Ульрих Е.А., Мухин А.А., Таратонов А.В., Шмидт А.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Саевец В.В., Важенин А.В., Ульрих Е.А., Мухин А.А., Таратонов А.В., Шмидт А.В.</copyright-holder><copyright-holder xml:lang="en">Саевец В.В., Важенин А.В., Ульрих Е.А., Мухин А.А., Таратонов А.В., Шмидт А.В.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.malignanttumors.org/jour/article/view/726">https://www.malignanttumors.org/jour/article/view/726</self-uri><abstract><p>Злокачественные опухоли яичников занимают 9 место в структуре заболеваемости и 6 место по смертности среди опухолей репродуктивной системы у женщин. Выживаемость больных раком яичников зависит от стадии опухолевого процесса, объема хирургического лечения, величины остаточной опухоли и от выбора метода лечения на первом этапе. В настоящее время при лечении злокачественных опухолей яичников на первом этапе следует стремиться к «агрессивной» хирургической тактике, направленной на удаление всех макроскопически определяемых опухолевых очагов с последующей химиотерапией. Однако при некоторых особенностях распространённости опухолевого процесса не всегда на первом этапе возможно выполнить данный вид хирургического лечения, что диктует необходимость выполнения тщательного инструментального обследования, позволяющего оценить возможность выполнения максимальной циторедукции. В данной работе проведен обзор оптимальных методов инструментальной диагностики и лечения пациентов с распространёнными формами рака яичников.</p></abstract><trans-abstract xml:lang="en"><p>Злокачественные опухоли яичников занимают 9 место в структуре заболеваемости и 6 место по смертности среди опухолей репродуктивной системы у женщин. Выживаемость больных раком яичников зависит от стадии опухолевого процесса, объема хирургического лечения, величины остаточной опухоли и от выбора метода лечения на первом этапе. В настоящее время при лечении злокачественных опухолей яичников на первом этапе следует стремиться к «агрессивной» хирургической тактике, направленной на удаление всех макроскопически определяемых опухолевых очагов с последующей химиотерапией. Однако при некоторых особенностях распространённости опухолевого процесса не всегда на первом этапе возможно выполнить данный вид хирургического лечения, что диктует необходимость выполнения тщательного инструментального обследования, позволяющего оценить возможность выполнения максимальной циторедукции. В данной работе проведен обзор оптимальных методов инструментальной диагностики и лечения пациентов с распространёнными формами рака яичников.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак яичников</kwd><kwd>ПЭТ-КТ</kwd><kwd>максимальная циторедукция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>рак яичников</kwd><kwd>ПЭТ-КТ</kwd><kwd>максимальная циторедукция</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Состояние онкологической помощи населению России в 2018 году. М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. илл. - 236 с.</mixed-citation><mixed-citation xml:lang="en">Состояние онкологической помощи населению России в 2018 году. М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. илл. - 236 с.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Саевец В.В., Важенин А.В., Чернова Л.Ф., Таратонов А.В. Мухин А.А., Ульих Е.А. Современные подходы к лечению распространенных форм рака яичников с применением ГИИХ под контролем ПЭТ-КТ. Собственный опыт. Журнал Злокачественные опухоли. - 2019. - Т.9.- №3. – С. 48-56.</mixed-citation><mixed-citation xml:lang="en">Саевец В.В., Важенин А.В., Чернова Л.Ф., Таратонов А.В. Мухин А.А., Ульих Е.А. Современные подходы к лечению распространенных форм рака яичников с применением ГИИХ под контролем ПЭТ-КТ. Собственный опыт. Журнал Злокачественные опухоли. - 2019. - Т.9.- №3. – С. 48-56.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Fischerova D, Zikan M, Semeradova I, Slama J, Kocian R, Dundr P. et al.//Ultrasound Obstet Gynecol, 2017; 49(2): 263–274.</mixed-citation><mixed-citation xml:lang="en">Fischerova D, Zikan M, Semeradova I, Slama J, Kocian R, Dundr P. et al.//Ultrasound Obstet Gynecol, 2017; 49(2): 263–274.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Michielsen K, Dresen R, Vanslembrouck R, De Keyzer F, Amant F. et al. Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer.//European Journal of Cancer, 2017; (83): 88-98.</mixed-citation><mixed-citation xml:lang="en">Michielsen K, Dresen R, Vanslembrouck R, De Keyzer F, Amant F. et al. Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer.//European Journal of Cancer, 2017; (83): 88-98.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Roze J. F. et al. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer //Cochrane Database of Systematic Reviews. 2018; 10.</mixed-citation><mixed-citation xml:lang="en">Roze J. F. et al. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer //Cochrane Database of Systematic Reviews. 2018; 10.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Nam E. J. et al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI // Gynecologic oncology. 2010; (116), 3: 389-394.</mixed-citation><mixed-citation xml:lang="en">Nam E. J. et al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI // Gynecologic oncology. 2010; (116), 3: 389-394.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lopez-Lopez V, Cascales-Campos PA , Gil J, Frutos L, Andrade RJ, Fuster-Quiñonero M et al. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue// European Journal of Radiology. 2016; 85 (10): 1824–1828.</mixed-citation><mixed-citation xml:lang="en">Lopez-Lopez V, Cascales-Campos PA , Gil J, Frutos L, Andrade RJ, Fuster-Quiñonero M et al. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue// European Journal of Radiology. 2016; 85 (10): 1824–1828.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sara E. Sponholtz, Ole Mogensen, Malene G. Hildebrandt Pernille T. Jensen. Clinical impact of pre treatment FDG PET/CT staging of primary ovarian, fallopian tube, and peritoneal cancers in women. Acta Obstetricia et Gynecologica Scandinavica (AOGS), 2019.</mixed-citation><mixed-citation xml:lang="en">Sara E. Sponholtz, Ole Mogensen, Malene G. Hildebrandt Pernille T. Jensen. Clinical impact of pre treatment FDG PET/CT staging of primary ovarian, fallopian tube, and peritoneal cancers in women. Acta Obstetricia et Gynecologica Scandinavica (AOGS), 2019.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bingxin Gu Lingfang Xia Huijuan Ge Shuai Liu. Preoperative PET/ CT score can predict complete resection in advanced epithelial ovarian cancer: a prospective study// Quantitative Imaging in Medicine and Surgery. 2020; 10(3): 743-753.</mixed-citation><mixed-citation xml:lang="en">Bingxin Gu Lingfang Xia Huijuan Ge Shuai Liu. Preoperative PET/ CT score can predict complete resection in advanced epithelial ovarian cancer: a prospective study// Quantitative Imaging in Medicine and Surgery. 2020; 10(3): 743-753.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Stefania Rizzo, Maria Del Grande, Lucia Manganaro, Andrea Papadia, Filippo Del Grande. Imaging before cytoreductive surger y in advanced ovarian cancer patients// Int J Gynecol Cancer. 2020; 30(1): 133–138.</mixed-citation><mixed-citation xml:lang="en">Stefania Rizzo, Maria Del Grande, Lucia Manganaro, Andrea Papadia, Filippo Del Grande. Imaging before cytoreductive surger y in advanced ovarian cancer patients// Int J Gynecol Cancer. 2020; 30(1): 133–138.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">M. Petrillo, G. Vizzielli, F. Fanfani, V. Gallotta, F. Cosentino, V. Chiantera, F. Legge, et al. Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: Proof of a concept.//Gynecol. Oncol. 2015; (139): 5-9.</mixed-citation><mixed-citation xml:lang="en">M. Petrillo, G. Vizzielli, F. Fanfani, V. Gallotta, F. Cosentino, V. Chiantera, F. Legge, et al. Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: Proof of a concept.//Gynecol. Oncol. 2015; (139): 5-9.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Elattar A. et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer //Cochrane database of systematic reviews. 2011; 8: 2А.</mixed-citation><mixed-citation xml:lang="en">Elattar A. et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer //Cochrane database of systematic reviews. 2011; 8: 2А.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Huo Y. R. et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis //European Journal of Surgical Oncology (EJSO). 2015; 41 (12): 1578-1589.</mixed-citation><mixed-citation xml:lang="en">Huo Y. R. et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis //European Journal of Surgical Oncology (EJSO). 2015; 41 (12): 1578-1589.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cardenas-Goicoechea J . et al. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis //Journal of robotic surgery. 2019; 13 (1): 23–33.</mixed-citation><mixed-citation xml:lang="en">Cardenas-Goicoechea J . et al. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis //Journal of robotic surgery. 2019; 13 (1): 23–33.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Chi D.S., Musa F., Dao F. et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) // Gynecol. Oncol. 2012; 124: 10–14.</mixed-citation><mixed-citation xml:lang="en">Chi D.S., Musa F., Dao F. et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) // Gynecol. Oncol. 2012; 124: 10–14.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao Y. et al. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis //Gynecologic and obstetric investigation. 2018; 83 (3): 209-219.</mixed-citation><mixed-citation xml:lang="en">Xiao Y. et al. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis //Gynecologic and obstetric investigation. 2018; 83 (3): 209-219.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Yang L. et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome //PloS one. 2017; 12 (10): e0186725.</mixed-citation><mixed-citation xml:lang="en">Yang L. et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome //PloS one. 2017; 12 (10): e0186725.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Тюляндина А.С. Клинические и биологические основы выбора рациональной терапии распространенного рака яичников: дис. … д-ра мед. наук. М., 2018. https://www.ronc.ru/upload/</mixed-citation><mixed-citation xml:lang="en">Тюляндина А.С. Клинические и биологические основы выбора рациональной терапии распространенного рака яичников: дис. … д-ра мед. наук. М., 2018. https://www.ronc.ru/upload/</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">iblock/58f/1.-Dissertatsiya-Tyulyandina-A.S.pdf (дата обращения: 29.11.2019).</mixed-citation><mixed-citation xml:lang="en">iblock/58f/1.-Dissertatsiya-Tyulyandina-A.S.pdf (дата обращения: 29.11.2019).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Du Bois A., Reuss A., Pujade-Lauraine E. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO) // Cancer. 2009; 115 (6): 1234–1244.</mixed-citation><mixed-citation xml:lang="en">Du Bois A., Reuss A., Pujade-Lauraine E. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO) // Cancer. 2009; 115 (6): 1234–1244.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">González MA. et al. Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): Final analysis of second progressionfree survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology. 2020; 31 (suppl_4): S1142-S1215.</mixed-citation><mixed-citation xml:lang="en">González MA. et al. Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): Final analysis of second progressionfree survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology. 2020; 31 (suppl_4): S1142-S1215.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Grimm C. et al. Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by timing of surgery and residual tumor status in the Phase III PAOLA-1 trial. SGO Meeting 2020, Abstract 34.</mixed-citation><mixed-citation xml:lang="en">Grimm C. et al. Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by timing of surgery and residual tumor status in the Phase III PAOLA-1 trial. SGO Meeting 2020, Abstract 34.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
